The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Usefulness of denosumab to nonsquamous non-small cell lung cancer patients with bone metastases.
 
Hibiki Udagawa
No Relationships to Disclose
 
Seiji Niho
Honoraria - AstraZeneca; Chugai Pharma; Hisamitsu Pharmaceutical; Lilly Japan; Nippon Boehringer Ingelheim; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Lilly Japan (Inst); Pfizer (Inst)
 
Keisuke Kirita
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - Nippon Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Shingo Matsumoto
Honoraria - Chugai Pharma; Lilly Japan
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Novartis (Inst); Oxford Oncology (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Takeda (Inst)
 
Hironobu Ohmatsu
No Relationships to Disclose
 
Koichi Goto
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); OxOnc (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)